CyberKnife and EDGE in stereotactic body radiotherapy for pancreas cancer: a comparison of plan quality

CURRENT STATUS: POSTED

Zhitao Dai
School of physics and technology, Wuhan University
daizt_sinap@163.com
ORCID: https://orcid.org/0000-0003-0554-689X

Li Ma
Cancer Hospital, Chinese Academy of Sciences, Shenzhen Center

Tingting Cao
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Lian Zhu
Shanghai East Hospital

Man Zhao
Chinese Academy of Medical Sciences, Shenzhen Center

Zhenguo Wang
Caner Hospital, Chinese Academy of Medical Sciences, Shenzhen Center

Ning Li
Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center

DOI:
10.21203/rs.3.rs-16442/v1

SUBJECT AREAS
Internal Medicine Cancer Biology

KEYWORDS
stereotactic body radiotherapy, EDGE, CyberKnife, pancreas cancer
Abstract
Purpose: To perform a comprehensive comparison of the different stereotactic body radiotherapy (SBRT) plans between the Varian EDGE and CyberKnife (CK) systems for pancreas cancer.

Materials and methods: Fifteen patients with pancreas cancer were selected in this study. The median planning target volume (PTV) was 28.688 cm³ (5.736 to 49.246 cm³). The SBRT plans for the EDGE and CK were generated in the Eclipse and Multiplan systems respectively with the same contouring and dose constrains for PTV and organ at risk (OAR). Dose distributions in PTV were evaluated in terms of coverage, conformity index (CI), new conformity index (nCI), homogeneity index (HI), and gradient index (GI). OARs, including spinal cord, bowel, stomach, duodenum and kidneys were statistically evaluated by different dose-volume metrics and equivalent uniform dose (EUD). The volume covered by the different isodose lines (ISDL) ranging from 10% to 100% for normal tissue were also analyzed.

Results: All SBRT plans for EDGE and CK met the clinical requirement for PTV and OARs. For the PTV, the dosimetric metrics in EDGE plans were lower than that in CK, except that D 99 and GI were slightly higher. The EDGE plans with lower CI, nCI and HI were superior to offer the better conformity and homogeneity for PTV. For the normal tissue, the CK plans were better at OARs sparing. The radiobiological indices EUD of spinal cord, duodenum, stomach, and kidneys were lower for CK plans, except that liver were higher. The volumes of normal tissue covered by medium ISDLs (with range of 20%~70%) were lower for CK plans while that covered by high and low ISDLs were lower for EDGE plans.

Conclusions: This study indicated that both EDGE and CK generated equivalent plan quality, and both systems can be considered as beneficial techniques for SBRT of pancreas cancer. EDGE plans offered the better conformity and homogeneity of dose distributions for PTV, while the CK plans could minimize the exposure of OARs.

1. Introduction
Pancreatic cancer is the fourth leading cause of cancer-related mortality worldwide with a 5-year
survival rate approximately 20% [1, 2]. For localized disease, surgery with complete resection represents the only potential treatment option associated with any substantive chance of cure [3, 4]. However, due to non-specific early symptoms and aggressive behavior of pancreatic cancer, most patients were diagnosed at relatively late stages [5]. Most studies have demonstrated that chemotherapy combined with radiation therapy is more effective than single-modality therapy, despite continuous controversies about the role of radiation therapy exist due to conflicting clinical outcomes [6, 7, 8, 9]. Surrounded by many important and radiosensitive gastrointestinal organs, such as duodenum and stomach, the conventional radiotherapy for pancreatic cancer seems not to effectively spare these organs while delivering high dose to target [7]. The advantage of fractionated radiation therapy [10, 11] is mainly that normal tissue has the ability to repair its DNA after radiation while malignant tissue not due to the inherent genomic instability. Compared with three dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT) can reduce the dose of normal organs surrounding tumor, and also minimize the toxicity of gastrointestinal organs [12]. Goto Y and Colbert L E [13, 14] had performed IMRT and 3DCRT for local pancreatic cancer, and compared dosimetry and clinical outcomes. They verified that IMRT offered better dose constrains for target and organs at risk (OAR) compared to 3DCRT. Brown and Coworkers [15] also demonstrated that with the technology of IMRT, the prescription dose could be increased to 64.8 Gy, while maintained dose limits of OARs including spinal cord, liver, kidneys, and small bowel. Although the IMRT provided a probability of better tumor control for locally pancreatic cancer, the organ motion and patient set-up errors during the treatment may affect the radiation dose of organs due to the complex site of OAR surrounding tumor [16]. As a new technique born of the synthesis of all of the above-mentioned advances, stereotactic body radiotherapy (SBRT) is becoming more widespread, and it is probably known as a promising method of radiotherapy for pancreatic cancer with greater normal tissue sparing [17, 18, 19, 20]. With a higher dose per fraction, the dose gradient of SBRT plans is steeper than other conventional radiation, and have the better dose constrains of normal structures [21]. Lin et al. demonstrated the SBRT have the advantage of improving the local control for pancreatic cancer compared to the IMRT [22]. Kumar et al. [23] similarly made a
dosimetric analysis of the SBRT plans with duodenal sparing using volumetric-modulated arc therapy (VMAT) and IMRT in locally advanced pancreatic cancer.

SBRT plans usually applied non-coplanar field arrangement, especially for the CyberKnife (Accuray, Inc, Sunnyvale) system [24]. With 6D robotic arm and accurate tracking techniques, the CyberKnife, a 6MV linear accelerator, has high precision for dose delivery with a large degree of freedom, and the capability of real-time tumor positioning and correction. Qing et al performed the SBRT plans for locally advanced unresectable pancreatic cancer with CyberKnife, and showed lower normal tissue toxicity [25].

As a culmination in the field of radiosurgery, EDGE (Varian Medical Systems, Palo Alto, CA) has advantages of safety, noninvasive, comfortable radiosurgery in the treatment of new experience. The general application of EDGE is the intracranial SRS technique, which can eliminate small lesions of intracranial accurately; Another application is the SBRT technique of real-time tracking and dynamic irradiation technology, focusing on body dynamic target area constantly [26]. This machine is equipped with flattening filter (FF) and flattening filter free (FFF) beams, and the high resolution multileaf collimators (MLC) of 120 leaves with 2.5 mm widths at the isocenter [27, 28, 29]. Thus it could deliver higher dose rates more effectively and accurately while improving the conformity of dose distribution to the target simultaneously [28].

Currently, there is no study directly comparing dose distributions of SBRT plans between the CyberKnife(CK) and EDGE systems. In our study, two series of SBRT plans were generated using CK and EDGE platforms, respectively. We evaluated the different dosimetric metrics for target and normal tissue, as well as analyzing the radiobiological indices to reflect the response of radiation therapy.

2. Materials And Methods

2.1. Patients data

This study performed a retrospective analysis of patients with pancreas cancer who had undergone SBRT. 15 patients with locally advanced unresectable pancreatic cancer were included in this study. CT simulation was performed on a Brilliance™ Big Bore 16-slice CT scanner (Philips, Amsterdam, the
Netherlands) with a slice thickness of 1.5 mm. Clinical target volume (CTV) and critical structures were contoured jointly by oncologist and radiologist based on the fusion of CT and magnetic resonance (MR) images on the MultiPlan® system (Accuray Inc., Sunnyvale CA; version 4.02). Planning target volume (PTV) were defined by expanding the GTV with 2 or 3 mm margin in all directions. The size of PTV ranged from 5.736 to 49.246 cm³ (median 28.688). The critical normal tissue include spinal cord, bowel, stomach, duodenum, left kidney, right kidney and spleen were outlined according the Radiation Therapy Oncology Group (RTOG) for pancreatic cancer [30].

2.2. SBRT planning

According to the different prescribed dose, fifteen patients were divided into three groups, and each group consisted of five patients. The prescription dose for the three groups were of 37.5Gy/5F, 35.0Gy/5F, 32.5Gy/5F, respectively. After importing all image data of 15 patients into two systems, CyberKnife (CK) and EDGE, different SBRT treatment plans were designed by the same medical physicists. The dose constrains of targets and normal tissue were set to meet the criteria of the RTOG 0848 and the report of AAPM Task Group No. 101 (AAPM TG-101)[31,32, 33], as shown in Table 1. The CK plans were designed in the Multiple TPS (version 4.0.2). The 6MV FFF photon beam was applied and dose rate was set to 800MU/min with one or two cones with size of 10∼30mm. Beside the dosimetric constraints listed in Table 1, five “shells” expanded isotropically from PTV were used to make steep dose fall-off gradient. At the end of the optimization, beams and time reduction were used to make the plan clinically practical. All CK plans were optimized using the sequential process with the ray tracing algorithm.

The plans for EDGE system were generated with the Varian Eclipse® system (Varian Medical Systems, Palo Alto, CA; version 13.5). A VAMT plan for each case was generated using two 360° arcs with the same isocentre at the geometric centre of PTV. The 10MV FFF photon beam was chosen with a high dose rate of 2400MU/min. All VMAT plans were optimized using the progressive resolution optimizer (PRO) and analytical anisotropic algorithm (AAA) with a grid size of 1.5 mm were applied in dose calculation. In order to make the plan comparisons valid, both CK and EDGE plans were normalized to ensure ≥95% of PTV covered by prescription dose.
2.3. Evaluation metrics of PTV

As were listed in Table 1 and 2, the coverage and mean dose ($D_{\text{mean}}$) of PTV, as well as doses covered 99%, 95%, 5% and 1% of PTV ($D_{99}$, $D_{95}$, $D_5$, $D_1$) of PTV were categorized for plan evaluation.

Meanwhile, the conformity index ($CI$), new conformity index ($nCI$), homogeneity index ($HI$), and gradient index ($GI$) were also used to quantify the plan quality. $CI$ and $nCI$ quantifying the target coverage and healthy tissue sparing were defined as follow [34]:

\[
CI = \frac{V_{R_s}}{V_{PTV}} \tag{1}
\]

\[
nCI = \left( \frac{V_{R_s}}{V_{PTV}} \right) / \left( \frac{V_{R_s}}{V_{PTV}} \right) \tag{2}
\]

where the $V_{R_s}$ is the volume covered by prescription isodose line (PIDL), $V_{PTV}$ is the target volume, and the $V_{R_s}$ is the volume of target covered by PIDL. Usually, $CI$ and $nCI$ values are greater than 1.0. Smaller $CI$ and $nCI$ imply a more conformal plan and the ideal values for both indices are 1.0.

The homogeneity index which mainly used to evaluate the degree of the dose uniformity inside the target volume [35] was defined as equation(3):

\[
HI = \frac{D_2 - D_{98}}{D_p} \tag{3}
\]

where the $D_x$ is the dose that covers $x$ percent volume of PTV, and the $D_p$ is the prescription dose of target. Usually, $HI > 0$, and $HI = 0$ means each voxel of target volume receives the same dose.

At the same time, in order to assess the degree of dose fall-off outsied the target volume , the gradient index has been applied, which is calculated according to the following equation[36]:

\[
GI = \frac{V_{50\%}}{V_{100\%}} \tag{4}
\]

where the $V_{x\%}$ is the absolute volumes covered by $x\%$ of PIDL. For SBRT plan, smaller value of $GI$ means steeper dose fall-off and better normal tissue sparing.
2.4. Evaluation metrics of OARs

The maximum dose ($D_{\text{max}}$) and mean dose ($D_{\text{mean}}$) of all the contoured OARs were accessed.

Moreover, organ specialized DVH metrics, for instance $D_{0.25\text{cc}}$ and $D_{1.2\text{cc}}$ of spinal cord, were also evaluated according to AAPM TG-101. The details of OAR evaluation metrics were listed in Table 2. At the same time, equivalent uniform dose (EUD) was applied to convert the heterogeneous dose distributions into homogeneous dose. Based on the phenomenological model introduced by Niemierko, the EUD is defined as follows[37]:

$$EUD = \left( \sum_{i=1}^{n} v_i EQD_i^a \right)^{1/a}$$

(5)

where $v_i$ is the percentage of voxels receiving dose $D_i$. The $v_i$ and $D_i$ values are acquired from the DVHs and the sum of $v_i$ over all voxels equals 1. And parameter ‘$a$’ denotes the seriality property for different organs, and is usually set to a positive value for OARs. The EQD is calculated as follows, which is defined as biologically equivalent dose of 2Gy per fraction:

$$EQD = D \times \frac{\left(\frac{\alpha + D}{\beta} \right)}{\left(\frac{\alpha}{\beta} + 2\right)}$$

(6)

Where $n$ denotes the number of fractions, The $\alpha/\beta$ is a parameter from the issue-specific Linear Quadratic (LQ) model of the certain organ, determining the fractionation sensitivity. The values of parameters $a$ and $\alpha/\beta$ were listed in Table 4 according to reference[38].

2.5 Volumes covered by different ISDL

To analyze the details of dose distribution outside PTV, the absolute volumes of normal tissue that covered by $x$ percent of prescription isodose lines ($V_x$) ranging from 100% to 10% with intervals of 10% were compared between CK and EDGE plans. Ratios between volumes of normal tissue ($V_x$) and PTV ($V_{\text{PTV}}$) were also calculated to minimize the effect resulted from different PTV volumes.

Meanwhile, effective distance $\Delta R_{\text{eff}}$ was applied to quantify the dose fall-off details of different ISDL,
which is defined as follow:

$$\Delta R_{\text{eff}} = R_{\text{ise}}^x - R_{\text{PTV}}$$  \hspace{1cm} (7)$$

Where $R_{\text{ise}}^x$ and $R_{\text{PTV}}$ were the equivalent radius of spheres with volumes of $V_x$ and $V_{\text{PTV}}$, which were calculated based on sphere volume formula $V=4\pi R^3/3$.

2.6. Statistical analysis

For those 15 patients with two different SBRT plans in EDGE and CK systems, a paired t-test statistical analysis were performed using the IBM SPSS statistical software version 21 (SPSS Inc., Armonk, NY) to determine the difference, and if P value < 0.05, it was consider to have the statistical significance. All datas were listed in terms of mean value±standard deviation (SD).

3. Results

In total, a retrospective analysis of 15 patients with pancreas cancer was performed. The treatment plans of SBRT were designed in CK and EDGE systems, respectively. Plans generated in both platforms could meet the clinical criteria of PTV coverage and OAR sparing. The median volume of tumor was 28.688 cm$^3$ (5.736 to 49.246 cm$^3$). All of CK and EDGE plans were normalized to ensure at least 95% of PTV covered by prescription dose.

3.1 Evaluation of PTV

The comparison of isodose lines from 30% to 100% of the prescription dose for a selected case was illustrated in Figure 1. It reveals that both plans have excellent conformity and adequate coverage for PTV. Besides, we can find that the 100% PIDL (with red color) of EDGE plan is closer to PTV boundary than that of CK plan.

The average DVHs of PTV for CK and EDGD plans are shown in Figure 2. From integral DVHs displayed in the upper row of Figure 2, we have found that PTV coverage of EDGE plans are a little higher than that of CK in all the three groups. Further, we have investigated the details of PTV DVHs in the way of differential as were displayed in the lower row of Figure 2, from which we may conclude that the voxel dose of EDGE plans are more closed to prescription dose than the one of CK. It is also indicated that both of the cold and hot point volumes of CK plans larger than those of EDGE plans. This means that
EDGE plans are more conformal and homogeneous.

The dosimetric metrics of PTV including $V_{100}$, $D_{\text{mean}}$, $D_{99}$, $D_{95}$, $D_{5}$ and $D_{1}$ are displayed in Figure 3 and Table 2. To ensure cases with different prescription doses are comparable, all of the dose-volume metrics are expressed with percentage values. It is indicated that PTV coverage ($V_{100}$) is slightly higher for CK, which may result from different normalization methods. Dosimetric metrics including $D_{\text{mean}}$, $D_{99}$, $D_{95}$, $D_{5}$ and $D_{1}$ are smaller for EDGE except that $D_{99}$ is a little higher compared with those of CK plans. This is consistent with Figure 2. Other evaluation indexes such as CI, nCI, HI and GI are displayed in Figure 4(a)~(d), and the statistical data is detailed in Table 2. The CI and nCI of PTV for EDGE plans are 0.986±0.019, 1.037±0.020, respectively, which are smaller than those of CK plans with 1.184±0.076 and 1.222±0.072 (as shown in Table 2). And HI of both plans are also compared, from which the values of 0.296±0.077 and 0.416±0.033 are obtained for EDGE and CK, respectively.

It can be concluded that EDGE plans are superior in terms of conformity and homogeneity. However, GI for CK plans are more lower than EDGE, which implies the steeper dose fall-off gradient.

3.2 Evaluation of OARs

The average DVHs of organs at risk including spinal cord, bowel, stomach, duodenum, Liner, left kidney, right kidney and spleen are displayed in Figure 5(a)~(h). And Table 3 shows the results of dose-volume parameters of normal tissue. All criteria of the dose constrain for normal tissue were achieved in both systems. Compared with CK plans, the dosimetric metrics of spinal cord including $D_{\text{max}}$, $D_{0.25cc}$, $D_{1.2cc}$ were slightly higher for EDGE plans with significant statistical differences, which indicates the decreased sparing of spinal cord with EDGE. From Table 3, the $D_{5cc}$ of bowel and the mean dose of bowel, stomach, liver, and kidneys are slightly lower for EDGE plans with statistical difference ($p<0.001$), but other dose-volume metrics shows no difference.

In order to further compare the dosimetric parameters of organ at risk for EDGE and CK, we calculated the radiobiological parameter EUD by the equation(5)~(6) according the DVHs of spinal cord, bowel, stomach, duodenum, Liner, left kidney, right kidney and spleen, and the results are showed in Table 4. From the data of Table 4, the EUD values of spinal cord, duodenum, stomach, left
and right kidneys are lower for CK plans, expect the liver having higher EUD value. And there are significantly statistic difference. But for bowel and spleen, both of two series plans have the similar value of dose-volume and no statistic difference.

3.3. Dosimetric comparison with different ISDL

The average volume of normal tissue covered by different prescription isodose lines are displayed in Figure 6. In the Figure 6(a) and (b), the EDGE plans have the less volumes of normal tissue for the lower and higher prescription isodose region than CK plans, which provide the superiority to control the hot spot of tumor. These results are also in consistent with the Figure 2 and 3. However, for the intermediate dose region with 20%~70% of prescription isodose, it is obvious that the volume of normal tissue received radiation dose for CK plans are less than EDGE plans, as accordance with the Figure 5 and Table 3. In the Figure 6(c), within the radius R of 0~1cm, the CK plans showed the steeper dose fall-off gradient, as same the shown in Figure 4. The average volumes, standard deviation(SD) and P values are listed in Table 5.

4. Discussion

In this study, we made a comprehensive plan quality comparison in terms of various dosimetric metrics for pancreatic cancer SBRT between Varian CyberKnife and EDGE systems. Both of the two techniques had the capability of producing clinically acceptable plans with adequate PTV coverage and OAR sparing. These results showed that EDGE plans offered the better conformity and homogeneity for PTV, while CK plans had slightly better dose coverage of PTV and the steeper dose fall-off gradient. For OARs, except $D_{5cc}$ of bowel and the mean dose of bowel, stomach, liver, and kidneys are slightly lower for EDGE plans, the rest dose-volume metrics, as well as EUD were all lower for CK plans. When investigating the details of dose distribution outside PTV, it was obtained that the volumes covered by intermediate ISDL (ranging from 20–70%) were much lower for CK plans, while the EDGE plans indicated superior sparing for lower and higher dose region.

Our data indicated that the EDGD plans had the better conformity and homogeneity compared to the CK plans. This may be related to the field arrangement and delivery techniques for different platforms. On the one hand, hundreds of non-coplaner field were used for CK plans while only two
coplaner 360° arcs were applied for EDGD plans. This results in that the entire dose being deposited within the plane of the arcs for EDGE plans, while the radiation dose was concentrated in the center of the target area with much bigger degree of freedom for beam directions. At the same time, the hot spot in CK may be a litter larger than that of EDGE. On the other hand, the collimators of the two systems are also very different. CK plans only adopted 1 ~ 2 circular cones for beam shaping, but for EDGE system is equiped with high definition HD120 MLCs with spatial resolution of 2.5mm[26], which may made the better conformity and homogeneity of PTV for EDGE simultaneously, as shown in Fig. 1 ~ 3.

For the two series of plans, the CK plans used the 6MV FFF beams, while the EDGE chose the 10MV FFF beams. When removing the flattening filter, it can offer increasing dose rate and make the beam profile more forward at the central axis. At the same time, there are other advantages for FFF beams, such as reduction of the scattered radiation and treatment head leakage [28]. With the 10MV FFF modes, it could result in the relatively lower radiation dose exposure for OARs, as well as for the integrated body. However, in this study, the EDGD plans did not show any superiority for OAR sparing. Our previous study regarding to localized prostate cancer showed that EDGE plans not only provided better conformity and homogeneity for PTV, but also steeper dose fall-off gradient and superior OAR sparing. The inconsistent results may partly due to the different shapes of PTV that affect the dose distributions. The shape of pancreatic cancer had a relatively regular shape, approximately ellipsoidal, so that both of the two series of plans were made to meet the dose constrains of PTV easily. In the Multiplan system, five ‘shells’ were applied to limit the dose outside PTV, which may lead to better normal tissue sparing.

The delivery efficiency of beam is one of the most significant differences between the CK and EDGE systems. The average treatment time of per fraction was 2 ~ 3 minutes approximately for the EDGE, and 40 ~ 50 minutes approximately for the CK according to our clinical experience. On the one hand, the reduction of average delivery time can alleviate the discomfort of patients during radiotherapy. On the other hand, the effects of intra-fractional organs motion would be reduced by decreasing the treatment time for EDGE [39-41].
Our results did show that a dose escalation of SBRT for pancreas cancer in EDGE and CK systems both could reach the clinical criteria. But there are still some limitations for this study. This study is a retrospective analysis and the SBRT plans for EDGE were not applied in clinical practice. Further studies were warranted to assess the clinical utility and radiobiological responses. Another limitation is that there is no consistent results for PTV margins and the organs motion [42, 43]. Whether patient specialized PTV margins could be obtain for different platforms, and how much the margins would affect the dose distribution for surrounding normal tissue will be the next tissue for our further study.

5. Conclusion
A comparative quantitative assessment of the dosimetric and radiobiological indices of SBRT plans for 15 patients with pancreas cancer between CK and EDGE systems. We confirm that radiotherapy systems with different characteristics should be investigated and utilized to help radiation oncologists choose a proper SBRT method for each individual patient to get better therapeutic effects. Although the CK system indicate better OAR sparing, the EDGE system can be regarded as an alternative option for SBRT of pancreas cancer, especially for patients who cannot remain lying in bed for a long time.

Declarations

**Ethics approval and consent to participate**

The study was approved by the institutional review board of our hospital.

**Consent for publication**

The consents for publication of data have been obtained from patients.

**Availability of data and materials**

Not applicable.

**Competing interests**

The authors state that they have no competing interests.

**Funding**

This work is supported by the National Natural Science Foundation of China (Grant No. 81871509), and China Postdoctoral Science Foundation (Grant No. 2018M640725).
**Authors’ Contributions**

Conception and design: Z.T. Dai, N. Li

Acquisition of data: Z.T. D., T.T. Cao, L. Zhu, M. Zhao.

Analysis of data: Z.T. Dai, M. Zhao, Z.G. Wang.

Writing, review and/or revision of the manuscript: Z.T. Dai, L. Ma, T.T. Cao, N. Li

All authors reviewed the manuscript.

**Acknowledgements**

No acknowledgement.

**References**

[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer statistics, 2014[J]. Ca A Cancer Journal for Clinicians, 2014, 62(1):10.

[2] Auriemma W S, Berger A C, Bar-Ad V, et al. Locally advanced pancreatic cancer.[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2005, 23(20):126-128.

[3] Sabater L, Muñoz E, Roselló S, et al. Borderline resectable pancreatic cancer. Challenges and controversies.[J]. Cancer Treatment Reviews, 2018.

[4] Lin Q J, Feng Y, Chen J, et al. Current status and progress of pancreatic cancer in China[J]. World Journal of Gastroenterology, 2015, 21(26):7988-8003.

[5] Krishnan S, Rana V, Janjan N A, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.[J]. Cancer, 2007, 110(1):47-55.

[6] Hammel P, Huguet F, van Laethem J L, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial [J]. Jama, 2016, 315(17):1844-1853.

[7] Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of Dosimetric Parameters Associated With Acute Gastrointestinal Toxicity and Upper Gastrointestinal Bleeding in Locally Advanced Pancreatic Cancer Patients Treated With Gemcitabine-Based Concurrent Chemoradiotherapy This work was presented at
the [J]. International Journal of Radiation Oncology Biology Physics, 2012, 84(2):369-75.

[8] Ben-Josef E, Schipper M, Francis I R, et al. A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer[J]. International Journal of Radiation Oncology Biology Physics, 2012, 84(5):1166-71.

[9] Dholakia A S, Chang D T, Goodman K A, et al. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma.[J]. Practical Radiation Oncology, 2013, 3(2):S4-S5.

[10] Trakul N, Koong A C, Maxim P G, et al. Modern radiation therapy techniques for pancreatic cancer.[J]. Gastroenterol Clin North Am, 2012, 41(1):223-235.

[11] Akushevich I, Kravchenko J, Akushevich L, et al. Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy [J]. International Journal of Radiation Oncology Biology Physics, 2012, 82(2):508-518.

[12] Yovino S, Poppe M, Jabbour S, et al. Intensity-Modulated Radiation Therapy Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers [J]. International Journal of Radiation Oncology Biology Physics, 2011, 79(1):158-162.

[13] Goto Y, Nakamura A, Ashida R, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer [J]. Radiation Oncology, 2018, 13(1):118.

[14] Colbert L E, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.[J]. Advances in Radiation Oncology, 2017, 2(3):403-415.

[15] Brown M W, Ning H, Arora B, et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma [J]. International Journal of Radiation Oncology Biology Physics, 2006, 65(1):274-283.

[16] Jones A O, Kleiman M T. Patient setup and verification for intensity-modulated radiation therapy (IMRT) [J]. Medical Dosimetry, 2003, 28(3):175-183.

[17] Dagoglu N, Callery M, Moser J, et al. Stereotactic Body Radiotherapy (SBRT) Reirradiation for
Recurrent Pancreas Cancer[J]. J Cancer, 2016, 7(3):283-288.

[18] Hajj C, Goodman K A. Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2015, 33(16):1737.

[19] Kim S K, Wu C, Horowitz D P. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist [J]. Journal of Gastrointestinal Oncology, 2016, 7(3):479.

[20] Moningi S, Dholakia A S, Raman S P, et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience [J]. Annals of Surgical Oncology, 2015, 22(7):2352.

[21] Milano M T, Constine L S, Paul O. Normal tissue toxicity after small field hypofractionated stereotactic body radiation [J]. Radiation Oncology, 2008, 3(1):36.

[22] Lin J C, Jen Y M, Li M H, et al. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer [J]. European Journal of Gastroenterology & Hepatology, 2015, 27(3):259-64.

[23] Kumar R, Wild A T, Ziegler M A, et al. Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis [J]. Medical Dosimetry, 2013, 38(3):243-250.

[24] Antypas C, Pantelis E. Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system [J]. Physics in Medicine & Biology, 2008, 53(17):4697-4718.

[25] Qing S W, Ju X P, Cao Y S, et al. Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study [J]. Radiation Oncology, 2017, 12(1):6.

[26] Wen N, Li H, Song K, et al. Characteristics of a novel treatment system for linear accelerator-based stereotactic radiosurgery[J]. Journal of Applied Clinical Medical Physics, 2015, 16(4):5313.

[27] Yin F F, Zhu J, Yan H, et al. Dosimetric characteristics of Novalis shaped beam surgery unit [J]. Medical Physics, 2002, 29(8):1729-1738.

[28] Georg D, Knöös T, Mcclean B. Current status and future perspective of flattening filter free photon beams [J]. Medical Physics, 2011, 38(3):1280-1293.
[29] Chang Z, Wang Z, Wu Q J, et al. Dosimetric characteristics of novalis Tx system with high definition multileaf collimator.[J]. Medical Physics, 2008, 35(10):4460-4463.

[30] Goodman K A, Regine W F. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer [J]. International Journal of Radiation Oncology Biology Physics, 2012, 83(3):901-8.

[31] Regine W, Lowy AM, et al. RTOG 0848: A phase III trial evaluating both erlotinib and chemoradiation as adjuvant treatment for patients with resected head of pancreatic cancer. RTOG, 2010.

[32] Ling T C, Slater J M, Mifflin R, et al. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848[J]. Journal of gastrointestinal oncology, 2015, 6(2):108.

[33] Stanley H, Benedict. Stereotactic body radiation therapy: The report of AAPM Task Group 101 [J], Phys Med.2010, 37(8).

[34] Feuvret L, Noël G, Mazeron J J, et al. Conformity index: a review [J]. International Journal of Radiation Oncology Biology Physics, 2006, 64(2):333.

[35] Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments [J]. Journal of Medical Physics, 2012, 37(4):207.

[36] Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index [J]. Journal of Neurosurgery, 2006, 105 Suppl: 194-201.

[37] Niemierko, A. (1999) A Generalized Concept of Equivalent Uniform Dose (EUD). Medical Physics, 26, 1100.

[38] Gary Luxton, Paul J Keall and Christopher R King. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Phys Med Biol, 2008;53:23.

[39] Li Y, Shi F, Tian Z, et al. SU-E-J-133: Evaluation of Inter- and Intra-Fractional Pancreas Tumor Residual Motions with Abdominal Compression[J]. Medical Physics, 2014, 41(6Part8):186-186.

[40] Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer.
[41] Fukada J, Kitago M, Sutani S, et al. Quantification of Interfraction and Intrafraction Pancreas Motion Using Pancreatic Stent[J]. International Journal of Radiation Oncology Biology Physics, 2015, 93(3):E178-E179.

[42] Scobie S, Adamson S, Malik J, et al. Intrafraction Prostate Motion during Radical Radiotherapy: Evaluation of Current Clinical Tolerance[J]. Clinical Oncology, 2015, 27(3):e5-e5.

[43] Minn A Y, Schellenberg D, Maxim P, et al. Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment[J]. American Journal of Clinical Oncology, 2009, 32(4):364.

Tables
Table1. Dose constrains of target and normal tissue for SBRT plans

| Structure       | Metrics              | Objective       |
|-----------------|----------------------|-----------------|
| PTV             | $V_{100}$(%)         | $\geq 95\%$    |
|                 | PIDL                 | $\sim 70\%$    |
| Spinal Cord     | $D_{\text{max}}$(Gy) | $< 27\text{Gy}$|
|                 | $D_{0.25\text{cc}}$(Gy) | $< 22.5\text{Gy}$ |
|                 | $D_{1.2\text{cc}}$(Gy) | 13.5Gy        |
| Duodenum        | $D_{\text{max}}$(Gy) | 32Gy           |
|                 | $D_{5\text{cc}}$(Gy) | $< 18\text{Gy}$ |
|                 | $D_{10\text{cc}}$(Gy) | $< 12\text{Gy}$ |
| Bowel           | $D_{\text{max}}$(Gy) | $< 35\text{Gy}$ |
|                 | $D_{5\text{cc}}$(Gy) | $< 19.5\text{Gy}$ |
| Stomach         | $D_{\text{max}}$(Gy) | $< 32\text{Gy}$ |
|                 | $D_{10\text{cc}}$(Gy) | $< 18\text{Gy}$ |
| Liver           | $V<17.5\text{Gy}(cc)$ | $> 700\text{cc}$ |
| Left kidney     | $D_{\text{mean}}$(Gy) | $< 12\text{Gy}$ |
|                 | $V>23\text{Gy}(\%)$ | $< 66.7\%$    |
| Right kidney    | $D_{\text{mean}}$(Gy) | $< 12\text{Gy}$ |
|                 | $V>23\text{Gy}(\%)$ | $< 66.7\%$    |
| Spleen          |                      | No constraint  |
$V_{xx}^*$, the percentage of PTV or OAR volume receiving xx% prescription dose; PIDL, Prescribed isodose line; $V_{xx\text{ Gy}}$, volume of PTV or OAR receiving at least xx Gy; $D_{xx\text{ cc}}$, dose of PTV or OAR covers xx cc volume.

Table 2. The dosimetric indexes comparison of PTV between Cyberknife and EDGE plans.

| Metrics   | CK+SD       | Edge+SD     | p     |
|-----------|-------------|-------------|-------|
| V100(%)   | 96.8±10.84  | 95.04±0.03  | 0.000 |
| Dmean(%)  | 123.91±1.97 | 112.32±3.39 | 0.000 |
| D99(%)    | 93.28±2.53  | 97.13±0.64  | 0.000 |
| D95(%)    | 102.92±1.40 | 100.02±0.01 | 0.000 |
| D5(%)     | 137.83±2.30 | 125.40±7.13 | 0.000 |
| D1(%)     | 139.42±2.04 | 129.27±7.42 | 0.000 |
| CI        | 1.184±0.076 | 0.986±0.019 | 0.000 |
| nCI       | 1.222±0.072 | 1.037±0.020 | 0.000 |
| HI        | 0.416±0.033 | 0.296±0.077 | 0.000 |
| GI        | 3.070±0.222 | 4.145±0.312 | 0.000 |

Table 3. The dosimetric metrics comparison of OARs between Cyberknife and EDGE plans.
| Structure        | Metrics | CK±SD        | Edge±SD       | p    |
|------------------|---------|--------------|---------------|------|
| Spinal Cord      | D<sub>max</sub> | 5.69±1.62    | 9.22±2.04     | 0.000|
|                  | D<sub>mean</sub> | 1.97±0.53    | 1.45±0.46     | 0.000|
|                  | D<sub>0.25cc</sub> | 5.12±1.49    | 8.39±1.79     | 0.000|
|                  | D<sub>1.2cc</sub> | 4.62±1.30    | 7.60±1.62     | 0.000|
| Duodenum         | D<sub>max</sub> | 16.22±6.36   | 19.89±5.95    | 0.140|
|                  | D<sub>mean</sub> | 3.61±1.43    | 3.49±1.64     | 0.847|
|                  | D<sub>5cc</sub> | 8.34±3.71    | 11.15±5.59    | 0.143|
|                  | D<sub>10cc</sub> | 6.66±3.18    | 8.58±5.13     | 0.271|
| Bowel            | D<sub>max</sub> | 19.98±5.25   | 20.56±2.80    | 0.516|
|                  | D<sub>mean</sub> | 2.81±0.75    | 1.63±0.59     | 0.000|
|                  | D<sub>5cc</sub> | 13.39±0.91   | 15.26±2.77    | 0.001|
| Stomach          | D<sub>max</sub> | 20.68±4.87   | 21.57±6.52    | 0.422|
|                  | D<sub>mean</sub> | 4.49±1.73    | 2.82±1.62     | 0.000|
|                  | D<sub>10cc</sub> | 11.82±2.96   | 11.07±4.32    | 0.347|
| Liver            | D<sub>mean</sub> | 2.67±1.23    | 1.23±0.20     | 0.000|
|                  | V<sub>&lt;17.5Gy</sub>(cc) | 1299.07±251.72 | 1299.07±252.67 | 0.306|
| Left kidney      | D<sub>mean</sub> | 2.21±0.76    | 0.39±0.20     | 0.000|
|                  | V<sub>&gt;23Gy</sub>(%) | 2.80±0.89    | 2.75±1.09     | 0.798|
| Right kidney     | D<sub>mean</sub> | 1.79±0.49    | 0.48±0.67     | 0.000|
|                  | V<sub>&gt;23Gy</sub>(%) | 2.30±0.62    | 2.47±1.15     | 0.337|
| Spleen           | D<sub>max</sub> | 7.56±2.20    | 8.23±3.60     | 0.450|
|                  | D<sub>mean</sub> | 2.16±0.77    | 1.70±1.19     | 0.027|

**Table 4.** Comparison of the EUD for OARs between CK and EDGE plans.
| Structure       | $\alpha/\beta$ | $n$  | EUD     |
|-----------------|----------------|------|---------|
|                 | CK±SD          | Edge±SD | p       |
| Spinal Cord     | 3              | 0.05  | 3.47±1.27 | 6.37±1.79 | 0.000 |
| Duodenum        | 4              | 0.15  | 7.73±2.29 | 9.12±1.98 | 0.001 |
| Bowel           | 4              | 0.15  | 10.34±3.30 | 10.54±3.75 | 0.722 |
| Stomach         | 4              | 0.15  | 8.47±3.59 | 12.41±6.08 | 0.005 |
| Liver           | 3              | 0.32  | 3.64±1.62 | 2.86±1.62 | 0.000 |
| Left kidney     | 3              | 0.7   | 2.06±0.73 | 3.06±1.42 | 0.001 |
| Right kidney    | 3              | 0.7   | 1.68±0.49 | 2.50±1.14 | 0.001 |
| Spleen          | 3              | 0.5   | 1.67±0.58 | 2.17±1.72 | 0.159 |

EUD, equivalent uniform dose; SD, standard deviation.

**Table 5. Volume comparison of normal tissue covered by different isodose lines.**

| Isodose | Volume(cc) | $V_x/V_{PTV}$ | $\Delta R_{Eff}(cm)$ |
|---------|------------|---------------|----------------------|
|         | CK±SD      | Edge±SD       | p                    | CK±SD | Edge±SD | p          | CK±SD | Edge±SD | p          |
| 100%    | 5.81±3.06  | 0.83±0.45     | 0.000                | 0.23±0.06 | 0.04±0.02 | 0.000 | 0.13±0.0 | 0.02±0.0 | 0.000 |
| 90%     | 12.57±5.32 | 8.11±3.15     | 0.000                | 0.50±0.08 | 0.33±0.06 | 0.000 | 0.26±0.0 | 0.18±0.0 | 0.000 |
| 80%     | 21.09±8.33 | 17.83±6.62    | 0.006                | 0.84±0.10 | 0.72±0.11 | 0.004 | 0.40±0.0 | 0.35±0.0 | 0.004 |
| 70%     | 31.75±12.25| 30.39±11.31   | 0.358                | 1.26±0.13 | 1.22±0.16 | 0.490 | 0.56±0.0 | 0.54±0.0 | 0.416 |
| 60%     | 46.06±17.62| 49.55±18.49   | 0.112                | 1.82±0.17 | 1.98±0.24 | 0.057 | 0.74±0.1 | 0.78±0.1 | 0.067 |
| 50%     | 67.74±25.89| 79.79±29.63   | 0.002                | 2.67±0.22 | 3.19±0.35 | 0.001 | 0.97±0.1 | 1.09±0.1 | 0.000 |
| 40%     | 106.21±40.7| 135.81±51.4   | 0.000                | 4.16±0.30 | 5.40±0.53 | 0.000 | 1.31±0.2 | 1.53±0.2 | 0.000 |
| 30%     | 193.03±74.9| 255.94±97.8   | 0.000                | 7.54±0.65 | 10.16±0.8 | 0.000 | 1.88±0.3 | 2.21±0.3 | 0.000 |
| 20%     | 553.84±264.| 590.73±212.   | 0.237                | 21.21±4.9 | 23.58±2.0 | 0.098 | 3.26±0.6 | 3.42±0.4 | 0.098 |
| 10%     | 2158.22±921| 1584.76±427   | 0.002                | 86.18±16. | 67.59±18. | 0.000 | 6.14±0.9 | 5.43±0.5 | 0.001 |

Figures
Figure 1

Comparison of planar dose distribution of one selected case. The upper row is for CK, and the lower row is for Edge.
The average DVHs curves of PTV for plans with prescription dose of 37.5Gy/5F (left column), 35.0Gy/5F (middle column) and 32.5Gy/5F (right column). The upper and lower rows represent the integral and differential DVHs, respectively. The black line is for CK, and the red line is for EDGE.
Comparison of different dosimetric metrics of PTV. (a) ~ (f) is for V100, Dmean, D99, D95, D5 and D1, respectively. The black line is for CK, and the red line is for EDGE.

Comparison different evaluation indexes of PTV for EDGE and CK plans. (a) Conformal index (CI), (b) new conformal index (nCI), (c) homogeneity index (HI), (d) gradient index (GI). The black color is for CK, and the red color is for EDGE.
The average DVH curves of normal tissue adjacent to tumor: (a) spinal cord, (b) duodenum, (c) bowel, (d) stomach, (e) liver, (f) left kidney, (g) right kidney, and (h) spleen. The black line is for CK, and the red line is for EDGE.

Comparison of normal tissue covered by different prescription isodose lines. (a) Absolute volumes (Vx), (b) the volume ratios (Vx/VPTV), (c) dose fall-off distance (ΔREff) for different isodose lines. The black line is for CK, and the red line is for EDGE.